Literature DB >> 10462360

Inhibitory effects of H2-receptor antagonists on platelet function in vitro.

K Nakamura1, H Kariyazono, T Shinkawa, T Yamaguchi, T Yamashita, O Ayukawa, Y Moriyama, G Yotsumoto, H Toyohira, A Taira, K Yamada.   

Abstract

To evaluate in vitro inhibitory effects of four types of histamine H2-receptor antagonist (H2-receptor antagonists), famotidine, roxatidine, cimetidine and ranitidine, on platelet function, we examined aggregating potency and P-selectin levels with agonist-induced aggregation. Ranitidine and cimetidine inhibited, in concentration of 0.35 mM, the secondary aggregation induced by 5 microM adenosine diphosphate (ADP), the aggregation induced by 1 microg/mL collagen and 3 microM arachidonic acid. All of H2-receptor antagonists inhibited, in concentration of 1.4 mM, the aggregation induced by ADP, collagen and arachidonic acid. Ranitidine and cimetidine reduced markedly, in same concentration, P-selectin levels after induction of aggregation by 5 microm ADP, 1 microg/mL collagen and 3 microM arachidonic acid. When classified by the strength of inhibitory action, ranitidine and cimetidine were strong, followed by famotidine and roxatidine. It is considered that inhibitory effects of H2-receptor antagonists on platelet function are weaker than those of acetylsalicylic acid (ASA), since ASA inhibited platelet aggregation in concentration of 100 microM. No relationship was observed between inhibitory effects of H2-receptor antagonists on platelet aggregation induced by above agonists and the presence or absence of imidazole ring in the chemical structure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462360     DOI: 10.1191/096032799678847069

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  4 in total

Review 1.  The Roles of Cardiovascular H2-Histamine Receptors Under Normal and Pathophysiological Conditions.

Authors:  Joachim Neumann; Uwe Kirchhefer; Stefan Dhein; Britt Hofmann; Ulrich Gergs
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

2.  No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.

Authors:  Moshe Rogosnitzky; Esther Berkowitz; Alejandro R Jadad
Journal:  JMIRx Med       Date:  2020-09-30

3.  Phenoxypropylamines: synthesis and antiulcer evaluation.

Authors:  Hui Zhang; Bao-Yan Zhang; Qian-Yun Zhang; Dong-Mei Zhao; Jia-Mei Wang
Journal:  Molecules       Date:  2009-05-13       Impact factor: 4.411

4.  Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point.

Authors:  Moshe Rogosnitzky; Esther Berkowitz; Alejandro R Jadad
Journal:  JMIR Public Health Surveill       Date:  2020-05-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.